Oppenheimer Rates BridgeBio Oncology Therapeutics (BBOT) buy

Oppenheimer has raised its price target for BridgeBio Oncology Therapeutics to $22, maintaining a 'buy' rating, a 195.90% upside from the current price.

By EarningsIQ Research Desk · Published Jun 22, 2026, 10:02 PM EDT · Updated Jun 25, 2026, 1:03 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Oppenheimer rated BridgeBio Oncology Therapeutics, Inc. ($BBOT) "buy" with a $22 price target on June 22, 2026.

Since the rating, $BBOT is down 2.7% after 1 week, up 13.1% after 1 month and down 64.2% to date (from the $7.87 close on Jun 22, 2026).

BBOT BridgeBio Oncology Therapeutics, Inc.

$2.82 -77.05% year to date

Daily close · Oct 16, 2026

Key Points

Oppenheimer raised its price target for BridgeBio Oncology Therapeutics, Inc. (BBOT) to $22, affirming a 'buy' rating on June 22, 2026.
Oppenheimer's $22 price target implies 195.90% upside from BridgeBio Oncology Therapeutics, Inc.'s ($BBOT) current $7.43 share price.
Shares of BBOT traded near $7.89 on Tuesday, with a market cap of about $630.4 million and a beta of 0.287.
Eventide Asset Management and others opened new positions in BBOT, and analysts have a strong buy consensus with a mean target price of $25.11.

Get $BBOT trade alerts by text

We text you when insiders, Congress or big funds trade $BBOT. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated BridgeBio Oncology Therapeutics, Inc. alert may contain errors. Disclosures

Oppenheimer has raised its price target for BridgeBio Oncology Therapeutics, Inc. (NasdaqGM:BBOT) to $22, maintaining a 'buy' rating. This update came from analyst Mazahir Alimohamed on June 22, 2026, as the firm continues to see potential in the biotechnology company's future.

Analyst rating track record

Oppenheimer vs. the S&P 500

YTD return +48.93% hypothetical

All-time return +132.25% S&P 500 +30.10%

vs. S&P 500 +102.15% ahead of the index

Hypothetical returns from Oppenheimer's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in BridgeBio Oncology Therapeutics

Several institutional investors have shown interest in BridgeBio Oncology Therapeutics. Eventide Asset Management, LLC opened a new position with 541,181 shares valued at approximately $4.7 million. Avidity Partners Management LP also initiated a stake with 43,853 shares worth about $392,484. Accent Capital Management, LLC and Barclays PLC joined in, opening new positions with 335 and 212 shares, valued at $2,998 and $1,897, respectively.

BridgeBio Oncology Therapeutics, Inc. Stock Up 55.9%

Shares of BridgeBio Oncology Therapeutics traded near $7.89 on Tuesday. The company, with a market cap of about $630.4 million, is in the biotechnology sector. It has a beta of 0.287, indicating lower volatility compared to the market. The stock has seen a 52-week low of $7.00 and a high of $14.87, with moving averages at $8.41 for 50 days and $10.55 for 200 days. The firm's financial health appears strong with a current ratio of 6.16 and a quick ratio of 5.835.

12-month forecast

$BBOT price target

BridgeBio Oncology Therapeutics, Inc. daily closes and this analyst's $22 target. Not advice.

Analysts Set New Price Targets

On June 22, 2026, Oppenheimer assumed coverage with a 'buy' rating and a $22 price target. Other analysts have similarly positive views, with Canaccord Genuity initiating coverage on May 11, 2026, with a 'buy' rating and a $23 target. HC Wainwright & Co. maintained a 'buy' rating with a $29 target on March 6, 2026. Overall, the stock has a strong buy consensus, with a mean target price of $25.11 across nine analyst opinions.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biotechnology company based in South San Francisco, California. It focuses on developing small-molecule therapeutics for treating various cancers, including non-small cell lung cancer and breast cancer. The company is led by CEO Dr. Pedro J. Beltran and employs 106 people. It is actively involved in clinical trials for its pipeline of innovative oncology treatments.

Bottom Line

Oppenheimer's new price target for BridgeBio Oncology Therapeutics underscores the firm's confidence in the company's potential. Investors often track such analyst ratings closely as they provide insights into a stock's future prospects. However, it's important to remember that these ratings are based on past and current data and may not reflect future market conditions.